(Reuters) – Eli Lilly and Co (N:) said late on Tuesday it had hired an independent consultant to review a plant producing its promising COVID-19 drug after receiving notices from the U.S. health regulator.
The company reiterated that it had not received a warning letter from the U.S. Food and Drugs Administration following inspections at the plant first revealed by Reuters last week.
The company, however, also reiterated that it had received an Official Action Indicated (OAI) notice from the FDA in relation to issues at its Branchburg plant in New Jersey.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.